Compare TFPM & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TFPM | PCVX |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.0B |
| IPO Year | N/A | 2020 |
| Metric | TFPM | PCVX |
|---|---|---|
| Price | $34.32 | $46.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $32.33 | ★ $101.67 |
| AVG Volume (30 Days) | 529.5K | ★ 1.5M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $344,001,000.00 | N/A |
| Revenue This Year | $42.63 | N/A |
| Revenue Next Year | $11.85 | N/A |
| P/E Ratio | $34.93 | ★ N/A |
| Revenue Growth | ★ 39.55 | N/A |
| 52 Week Low | $14.51 | $27.66 |
| 52 Week High | $35.77 | $93.77 |
| Indicator | TFPM | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 62.09 | 54.15 |
| Support Level | $32.95 | $42.40 |
| Resistance Level | $35.77 | $45.15 |
| Average True Range (ATR) | 1.23 | 1.95 |
| MACD | -0.05 | -0.30 |
| Stochastic Oscillator | 65.05 | 68.65 |
Triple Flag Precious Metals Corp is a streaming and royalty company focused on precious metals. Its revenues are largely generated from a diversified portfolio of properties in Australia, Canada, Colombia, Cote d'Ivoire, Mexico, Mongolia, Peru, South Africa, and the United States. Its diversified portfolio of streams and royalties comprises long-life mining assets, including the Northparkes copper-gold mine in Australia, the Cerro Lindo polymetallic mine in Peru, the Fosterville gold mine in Australia, the Buritica gold mine in Colombia, and the Impala Bafokeng Operations in South Africa among others. A majority of its revenue is derived through its interests in various gold streams. Geographically, the company derives maximum revenue from Australia, followed by Peru and other regions.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.